• CHMP takes negative view on Sarepta’s DMD therapy pharmatimes
    May 07, 2018
    Sarepta has indicated that there could be a delay to getting its Duchenne muscular dystrophy therapy Exondys approved in Europe, revealing that the European Medicine Agency’s Committee for Medicinal Products for Human Use’s trend vote was negative.
PharmaSources Customer Service